prenetics global ltd - PRE

PRE

Close Chg Chg %
25.62 -0.48 -1.87%

Open Market

25.14

-0.48 (1.87%)

Volume: 28.40K

Last Updated:

Sep 9, 2026, 10:04 AM EDT

Company Overview: prenetics global ltd - PRE

PRE Key Data

Open

$25.50

Day Range

25.10 - 25.96

52 Week Range

8.20 - 27.24

Market Cap

$436.13M

Shares Outstanding

17.14M

Public Float

13.29M

Beta

0.31

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$4.17

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

282.67K

 

PRE Performance

1 Week
 
0.71%
 
1 Month
 
40.31%
 
3 Months
 
18.45%
 
1 Year
 
154.29%
 
5 Years
 
N/A
 

PRE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About prenetics global ltd - PRE

Prenetics Global Ltd. is a health sciences company, which engages in providing consumer health products and services. The firm offers scientifically formulated supplements under the IM8 brand, sports nutrition products under the Europa platform, and direct-to-consumer DNA tests through the CircleDNA brand. It is also involved in establishing a Bitcoin treasury for the exploration of applications within the healthcare ecosystem. The company was founded by Sheng Wu Yeung and Chi Hung Tzang in 2014 and has dual headquartered in Charlotte, the United States and Hong Kong.

PRE At a Glance

Prenetics Global Ltd.
K11 Atelier King's Road
Hong Kong,
Phone 852-2210-9588 Revenue 92.39M
Industry Financial Conglomerates Net Income -37,709,000.00
Sector Finance 2025 Sales Growth 201.721%
Fiscal Year-end 12 / 2026 Employees 98
View SEC Filings

PRE Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.396
Price to Book Ratio 1.684
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.443
Enterprise Value to Sales 1.728
Total Debt to Enterprise Value 0.011

PRE Efficiency

Revenue/Employee 942,755.102
Income Per Employee -384,785.714
Receivables Turnover 21.516
Total Asset Turnover 0.44

PRE Liquidity

Current Ratio 2.967
Quick Ratio 2.722
Cash Ratio 2.205

PRE Profitability

Gross Margin 50.387
Operating Margin -41.433
Pretax Margin -37.832
Net Margin -40.815
Return on Assets -16.194
Return on Equity -20.791
Return on Total Capital -21.474
Return on Invested Capital -20.574

PRE Capital Structure

Total Debt to Total Equity 1.129
Total Debt to Total Capital 1.117
Total Debt to Total Assets 0.857
Long-Term Debt to Equity 0.279
Long-Term Debt to Total Capital 0.276
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Prenetics Global Ltd - PRE

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
275.76M 21.74M 30.62M 92.39M
Sales Growth
- -92.12% +40.83% +201.72%
Cost of Goods Sold (COGS) incl D&A
144.21M 12.91M 20.21M 45.84M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
7.54M 7.79M 5.93M 2.34M
Depreciation
5.99M 5.88M 4.02M 1.92M
Amortization of Intangibles
1.56M 1.91M 1.91M 421.00K
COGS Growth
- -91.05% +56.48% +126.85%
Gross Income
131.55M 8.83M 10.42M 46.55M
Gross Income Growth
- -93.29% +17.95% +346.98%
Gross Profit Margin
+47.71% +40.61% +34.01% +50.39%
2022 2023 2024 2025 5-year trend
SG&A Expense
124.88M 61.34M 61.30M 84.83M
Research & Development
15.52M 11.66M 10.55M 5.04M
Other SG&A
109.36M 49.68M 50.76M 79.80M
SGA Growth
+3,067.05% -50.88% -0.06% +38.38%
Other Operating Expense
- - - -
-
Unusual Expense
185.65M 7.68M 8.82M (2.95M)
EBIT after Unusual Expense
(178.98M) (60.20M) (59.71M) (35.33M)
Non Operating Income/Expense
(130.03K) 4.51M 3.99M 614.00K
Non-Operating Interest Income
472.19K 3.92M 2.04M 1.04M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.20M 119.66K 203.00K 241.00K
Interest Expense Growth
- -97.15% +69.64% +18.72%
Gross Interest Expense
4.20M 119.66K 203.00K 241.00K
Interest Capitalized
- - - -
-
Pretax Income
(183.31M) (55.81M) (55.92M) (34.95M)
Pretax Income Growth
-5,442.27% +69.55% -0.20% +37.50%
Pretax Margin
-66.47% -256.68% -182.63% -37.83%
Income Tax
7.15M (269.36K) (7.87M) 34.00K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
7.43M 46.44K (7.41M) 54.00K
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
(279.63K) (315.80K) (466.00K) (20.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(190.45M) (56.40M) (49.83M) (36.25M)
Minority Interest Expense
(54.000000000499995) (2.05M) (3.50M) (2.27M)
Net Income
(190.45M) (54.35M) (46.33M) (33.98M)
Net Income Growth
-5,658.36% +71.46% +14.76% +26.65%
Net Margin Growth
-69.06% -249.95% -151.29% -36.78%
Extraordinaries & Discontinued Operations
- (8.38M) 22.00K (3.73M)
Discontinued Operations
- (8.38M) 22.00K (3.73M)
Net Income After Extraordinaries
(190.45M) (62.72M) (46.30M) (37.71M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(190.45M) (62.72M) (46.30M) (37.71M)
EPS (Basic)
-37.5699 -5.5774 -3.7059 -2.6835
EPS (Basic) Growth
-4,190.27% +85.15% +33.56% +27.59%
Basic Shares Outstanding
5.07M 11.25M 12.49M 14.05M
EPS (Diluted)
-37.5699 -5.5774 -3.7059 -2.6835
EPS (Diluted) Growth
-4,190.27% +85.15% +33.56% +27.59%
Diluted Shares Outstanding
5.07M 11.25M 12.49M 14.05M
EBITDA
14.21M (44.72M) (44.96M) (35.94M)
EBITDA Growth
+460.46% -414.62% -0.54% +20.06%
EBITDA Margin
+5.15% -205.67% -146.83% -38.90%

Snapshot

Average Recommendation BUY Average Target Price 35.25
Number of Ratings 4 Current Quarters Estimate -0.798
FY Report Date 09 / 2026 Current Year's Estimate -3.46
Last Quarter’s Earnings -0.53 Median PE on CY Estimate N/A
Year Ago Earnings -3.79 Next Fiscal Year Estimate -1.646
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate -0.80 -0.69 -3.46 -1.65
High Estimates -0.51 -0.36 -2.88 -0.72
Low Estimate -1.51 -1.58 -5.23 -4.41
Coefficient of Variance -50.54 -74.40 -28.82 -94.61

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 3
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Prenetics Global Ltd - PRE

Date Name Shares Transaction Value
Jun 17, 2026 David Eric Vanderveen Director 45,249 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 17, 2026 David Eric Vanderveen Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Prenetics Global Ltd in the News